A Phase IIIb Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Xolair in Subjects with Moderate to Severe Persistent Asthma who are Inadequately Controlled with High-Dose Inhaled Corticosteroids and Long-Acting Beta-Agonists

Grants and Contracts Details

StatusFinished
Effective start/end date9/1/066/30/10

Funding

  • Genentech Inc: $74,119.00